Media coverage about Akari Therapeutics (NASDAQ:AKTX) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akari Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.4203458922338 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Akari Therapeutics (AKTX) opened at $4.33 on Friday. The firm has a market cap of $53.35, a P/E ratio of -15.46 and a beta of -9.06. Akari Therapeutics has a one year low of $3.18 and a one year high of $22.20.
A number of analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Chardan Capital reaffirmed a “neutral” rating on shares of Akari Therapeutics in a research note on Sunday, September 17th. William Blair raised shares of Akari Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, September 22nd. ValuEngine raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 price target on shares of Akari Therapeutics in a research note on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $7.50.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/12/30/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-akari-therapeutics-aktx-share-price.html.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.